KALO yields 666666.67% · PFE yields 6.13%● Live data
📍 KALO pulled ahead of the other in Year 1
Combined, KALO + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KALO + PFE for your $10,000?
Kallo Inc., together with its subsidiaries, focuses on developing medical information technology software. The company's products in development include Electronic Medical Records (EMR) Integration Engine, a software, which connects various other applications in or outside a hospital/clinic with the EMR system; Communicable and Infectious Disease Information Management System, an Internet-based solution for monitoring and managing communicable and infectious disease information; and Clinical-Care Globalization, a clinical-care globalization technology. Its products also include MC-Telehealth, a mobile clinic with telehealth system technology; Kallo Integrated Delivery System (KIDS), a technology and process framework that defines and describes the component parts of the various products and services; and KIDS Global Tele-Health Ecosystems, a Tele-health Program that encompasses various technologies and administrative processes needed to deliver virtual medical care, health promotion/prevention, and other patient education to KIDS patients. The company was formerly known as Diamond Technologies Inc. The company was incorporated in 2006 and is headquartered in Toronto, Canada.
Full KALO Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.